Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study

Background: Pyrotinib, a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor, shows encouraging anticancer activity and acceptable tolerability in multiple phase II and phase III randomized clinical trials, but the real-world data of pyrotinib, especially the outcomes in HER2-positive metast...

Full description

Bibliographic Details
Main Authors: Qiongwen Zhang, Ping He, Tinglun Tian, Xi Yan, Juan Huang, Zhang Zhang, Hong Zheng, Xiaorong Zhong, Ting Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Pharmacology
Subjects:
HER2-positive breast cancer
real-world studies
brain metastase
pyrotinib
tyrosine kinase inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1100556/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1100556/full

Similar Items